As someone who works in communications, I’ve watched this all unfold with a growing sense of urgency, not just because it affects my work, but because it affects the work of the entire ecosystem, from startups trying to commercialize to scientists and innovators trying to solve our biggest planetary problems.

We often talk about climate solutions needing scale. But before they scale, they need visibility. They need resonance. They need the world to understand why they matter.

Communicators as Ecosystem Builders

Marketing and communications professionals in the climate space have always worn many hats: translator, storyteller, advocate, pressure-tester. But lately, I’ve started to see our role differently: we are infrastructure. The strength of the message can determine the strength of the movement.

In Israel, where I work with several climate tech companies, there is no lack of innovative ventures; startups are tackling everything from water quality and waste to sustainable food systems and energy efficiency. But too often, their stories don’t reach the audiences that matter.

Whether it’s a lack of media attention, limited investor familiarity, or messaging that doesn’t translate across markets, the result is the same: solutions that could make a global impact remain under the radar. Recent research highlights that communication barriers, including conflicting values and lack of emotional engagement, are among the biggest obstacles to climate action.

This is a stark reminder of how critical effective, strategic communications is for companies needing that break. We can’t assume the science will speak for itself. Our job is to help it connect.

Tell the Story Behind the Science and Tech

Technical breakthroughs are important. But if we don’t communicate the human stakes — if we can’t answer “why does this matter, now?” — then even the most brilliant solutions will get buried in white papers and pitch decks.

Take Amai Proteins, an Israeli innovator creating sweet proteins that offer a healthier alternative to sugar. On the surface, that’s a biochemistry story. But it’s also a public health story; excess sugar consumption is linked to rising rates of obesity, diabetes, and cardiovascular disease, all of which disproportionately affect low-income communities and strain healthcare systems.

It’s a consumer behavior story, too. Shifting tastes and nutritional preferences are driving the food industry to rethink its ingredients, and “clean label” alternatives are in high demand.

Even RFK Jr., despite the controversy surrounding many of his opinions, is taking on food system reform, moving to eliminate dyes and other additives and expressing that he’d love to see sugar eliminated from the American diet.

And yes, it’s a climate resilience story. Sugarcane and sugar beet farming are resource-intensive crops that require large amounts of land, water, and fertilizer, all of which are vulnerable to climate disruptions. Replacing them with a low-footprint, precision-fermented protein could ease pressure on ecosystems and improve food system sustainability.

These are opportunities for communicators to widen the frame and show how innovations intersect with public values. That’s how a single ingredient becomes part of a bigger story.

Make Climate Action “Cool”

In a world drowning in doomscrolling, climate urgency isn’t enough. People want hope, and they want to feel like they’re part of something that’s not just necessary, but exciting.

We saw this with Tesla and the early days of the electric vehicle market. EVs didn’t catch on because people suddenly got worried about emissions; they caught on because someone made them desirable.

As marketers, we have the power to do the same for other sustainable technologies: to make algae cleanup, biodegradable packaging, or atmospheric water generation feel like the future, not a compromise.

Speak Across the Divide

Many of us are communicating in fragmented markets. Different regions, different priorities, different regulatory directions. But the best messaging finds common truths: Clean water. Job creation. Community resilience.

If you start the story with a universally accepted premise, you’ve created a foundation of trust from which to build.

FireDome, an Israeli startup inspired by the country’s Iron Dome missile defense system, offers a perfect example of this approach. FireDome has developed an AI-assisted solution to detect and suppress wildfires autonomously, addressing the increasing frequency and intensity of such events due to climate change — something we saw clearly in Israel last week.

FireDome’s story tightly aligns a climate solution with community benefits. Everyone can agree that defending against wildfires is a necessity to protect property and lives.

That’s because the impacts are clear. Last year’s wildfire, which raged through Southern California, left entire communities in ashes, dozens of people killed, over 150 thousand people displaced, and damages estimated between $250-$275 billion, according to AccuWeather.

The value of proactively defending against wildfires quickly becomes obvious. The alignment between technological outcomes and community values exemplifies how climate tech can build long-term momentum and break through with target audiences by highlighting these tangible benefits.

Building Communications into the Business Model

Startups often focus intensely on R&D, product-market fit, and fundraising — and rightly so. But communications can’t just be an add-on, revisited only when there’s “good news” to share.

If we believe climate solutions are essential, then we need to treat communications as essential, too –not an afterthought or a slide at the end of the pitch deck, but a foundational part of the company’s infrastructure.

Strategic communications, embedded early, does more than explain what a company does; it shapes how it’s understood by investors, partners, policymakers and the public.

The right narrative can open doors, build credibility, and help a startup punch above its weight. Because climate solutions don’t just need to work. They need to land. And that’s where strong, unifying, value-driven messaging makes all the difference.

The post Why Israel’s Brilliant Climate Solutions Are Still Invisible appeared first on Medika Life.

We are a species enamored with technology. I count myself among the early adopters who eagerly embraced gadgets promising to reshape how we live and heal. I owned an Apple Newton decades before smartphones became second nature. I strapped on a Fitbit long before step-counting became a cultural norm. I’ve carried an AliveCor device to track my heart rhythm because I care about heart health.

I’m fascinated by AI and impressed by the capabilities of ChatGPT and other large language models. But through all of it, a pattern emerges: while we sprint forward with healthtech innovation, we often overlook the element that gives health its soul—human empathy.

Hollywood’s visions of the future play out that tension. Films like iRobot and Outside the Wire imagine a world where advanced technology surrounds humans. Yet even in these hyper-connected futures, the human spirit, judgment and emotional resonance triumph over computation. Tech may win the movie battle, but empathy wins humanity’s greatest challenges.

So, the question becomes: in our real love affair with technology, how do we ensure that it doesn’t diminish our humanity but enhances it?

Digital Health’s Expanding Horizon

Health delivery is at a crossroads. On one hand, we are real-time participants in a sea-changing Cambrian explosion of innovation—AI models reading radiology scans, wearable devices transmitting real-time health data from patient to provider, voice assistants aiding mental health, AI tools “scraping” data from EMRs and predictive algorithms alerting physicians to early signs of disease. On the other hand, the average patient still struggles to schedule an appointment, reach a care coordinator, navigate their health insurance coverage or feel heard during a clinical encounter.

Digital health evolves faster than we can emotionally and ethically integrate into the care journey. As Hal Wolf, CEO of global NGO HIMSS, said in a 2025 HIMSS Europe keynote, “Old Organization + New Technology = Expensive Old Organization.” The implication is clear: technology alone is not transformation. It is a tool that is only as effective as the system and the people who apply it with purpose.

The Role of Emotion in Healing

John Nosta, a leading innovation theorist and founder of NostaLab, explores health decisions’ emotional and cognitive complexity in his essay Unraveling the Human Mind. He highlights the importance of understanding emotions like joy, guilt, and envy in AI development, reminding us that behavior is not driven solely by data but by deeply human emotional processes. This insight is critical: health behaviors—whether quitting smoking, taking medication, or attending a follow-up appointment—are deeply influenced by fear, hope, anxiety, trust and love.

AI can surface patterns, but it cannot feel. It can summarize a patient’s medical history, but cannot detect the tremble in their voice when they say, “I’m scared.” We must not confuse intelligence with insight or information with understanding.

Empathy as a Design Principle

For health tech to reach its most significant potential, we must design systems that understand and adapt to the human condition. That means:

Unfortunately, many current implementations miss the mark. A chatbot that dismisses a patient’s concerns with canned responses doesn’t reflect innovation—it reflects embedded institutional indifference. An app that tracks glucose but fails to create bridges to a community of support doesn’t reflect progress—it reflects a missed opportunity for connection and adherence.

The Power of AI and LLMs

Tom Lawry, former National Director for AI in Health & Life Sciences at Microsoft, captures this idea succinctly: “AI can automate highly repetitive activities and augment activities that are more highly varied and require a higher level of problem solving.” This duality reflects the essence of digital health transformation—technology that supports human expertise, not replaces it.

When used with intention, large language models like ChatGPT can democratize information, translate medical jargon, and surface unseen risks. They are powerful co-pilots in care. But they lack the capacity for compassion and their accuracy rests solely with the people designing the system.

I’ve often said that communication is the currency of care. That truth remains. The best outcomes emerge not from algorithms alone but from conversations between doctors and patients, health systems and communities, policymakers and people. Technology can facilitate these conversations, but it cannot replace them.

Leadership Needed

This is a call to the architects of our health future: More than “Don’t forget the patient, the caregiver, or the person behind the data,” people must be at the center of the action. We must remember that we are always people, only sometimes patients. Therefore, we need leaders—inside industry, government, academia and advocacy—who understand that digital transformation must be human-centered.

At the intersection of health and technology, we need humility. We need to listen more, build thoughtfully and measure success not just by the speed of a process or precision of a model, but by the quality of life it helps sustain and save.

Reimagining the Health-Tech Love Story

Our fascination with technology isn’t wrong. It’s natural. Much like the cinematic heroes in iRobot and Outside the Wire, we are drawn to machines’ capabilities but are also reminded that their greatest strengths emerge when paired with human insight. In those stories, it is not the tech that ultimately saves the day but the human instinct for empathy, ethics and engagement.

Progress is essential. But as we reimagine the health ecosystem, we must write a new love story—one where technology and empathy are co-stars, not competitors. One where innovation is in service of intimacy, and the promise of AI is fulfilled not in clinical outputs, but in human outcomes.

As someone who has watched health tech innovation unfold through the decades—from Apple Newton to neural networks—I remain hopeful. But hope, like health, is a human trait. It can’t be programmed. It must be lived.

Let’s remember that healing is not just about fixing bodies. It’s about touching hearts. Let’s code for that.

The post Human First: Reclaiming Empathy in Our Love Affair with Health Tech appeared first on Medika Life.

President Trump’s executive order could result in higher US medicines prices because big data will allow payments to be linked more closely to the real value a medicine delivers.

President Trump’s executive order is short on specifics but Bloomberg says that he will direct the US Trade Representative and the US Department of Commerce to take action on “unreasonable or discriminatory policies that suppress drug prices overseas.” Trump is also asking the Department of Health and Human Services to “facilitate direct drug sales to consumers at lower prices paid abroad.”

Pharmaceutical companies look as if they are charging more in the US than in the rest of the world for medicines protected by patents; sometimes they are not. Recently, I was with a client’s US and European commercial teams. With some trepidation, the UK GM announced the price he had negotiated with NICE, the British pricing authority. It was less than half the US list price but, the US general manager said that it was higher than the average price the company actually received in the US. The difference was skimmed off by what economists call “rent seekers” — companies that add no value but are able to add fees or a mark up. These parasitical pharmacy benefits managers and insurers are politically well connected and it has proved very difficult to cut them out of the US supply chain.

Does the US want medicines priced the way they are in the rest of the world?

The American system, beyond big federal programmes, relies on prices that are set through these one-on-one negotiations with various actors who can permit or block access for patients. In most of the rest of the rich world, medicines prices are set for almost all prescriptions through a system of health technology assessments (HTAs). These HTAs typically rely on some mix of assessing the true incremental value of a new medicine and estimating the savings that it could generate in other parts of the health system.

In the UK, for example, NICE typically considers a medicine cost-effective if its incremental cost-effectiveness ratio (ICER) falls between £20,000 and £30,000 per quality-adjusted life year saved (QALY). Interventions below £20,000/QALY are generally approved, while those above £30,000 require additional justification. It may accept ICERs up to £50,000 per QALY for severe conditions such as cancer or neurological illnesses or where it is difficult to measure the benefit exactly. In theory, a QALY equates to one year of life in perfect health. Two years at about 50 percent of perfect health (measured according to criteria such as pain, mobility and self-care) would be one QALY, for example.

Irish agencies require hospitals to consider the broader impact of drug choices on the entire healthcare system, including potential savings from reduced admissions or procedures. Most other countries factor these elements into decisions too. A 2015 study of 15 rich countries concluded that new medicines launched between 1982 and 2015 had saved about five times as much in averted health system costs as they had cost.

If those HTA criteria were applied widely in the US, prices would be much higher than they are in Europe. In the US, life expectancy is growing faster than healthy life expectancy — Americans are sicker for more of their lives than are most people in the world, so the cost of mitigating that poor health will be higher. There is a wealth of information in the International Longevity Centre UK’s Healthy Ageing & Prevention Index. American healthcare costs are much higher than they are anywhere else in the world, so the savings achieved by medicines will be even more impressive.

The real economic benefits of new medicines

What none of the HTA systems yet take into account are the wider societal benefits of prevention and treatment — it is often seen as too complicated. As Professor Rifat Atun and others wrote recently, “an important but often-overlooked mechanism is the benefit of health investments on the broader economy through influences on supply and demand across various other sectors of a country’s economy.”

“Adult immunisation programmes across ten countries and four vaccines showing that [these programmes] offset their costs multiple times through benefits to individuals, the healthcare system, and wider society,” a 2024 paper from the Office of Health Economics reported. “In particular, benefit-cost analysis of the same vaccines showed that adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised,” it concluded

Most health spending is on older people. They, on average, spend more of their income than do younger people so they are disproportionately important drivers of economic growth. They also provide a very large proportion of volunteer hours that enable younger people, especially women, to work more. As experts at Germany’s pioneering WifOR Institute said recently about cancer treatments in Germany, “health investments [are a] driver of economic stability and growth.”

The US is the world’s biggest economy so it realises more benefits from innovative medicines than other countries do. These benefits are getting easier to measure and quantify too: big data means we can track prevention and treatment success and its knock-on impacts throughout the economy more easily month by month.

Obstacles to the executive order

Is this executive order meant to effect change or to distract from other developments? It is too early to say.

Congress may not agree to government taking a role in setting prices outside Medicare and Medicaid, but those still account for about 40 percent of US medicines spending. The Biden Administration initiated negotiation for some medicines for federal programmes and that could probably be extended by executive action.

It is easy to talk about enabling Americans to buy medicines from abroad but that requires the consent of the countries from which they are buying. Canadian or British prices are negotiated based on different health system costs and economic benefits; it is unlikely that foreign governments will want to make it easier for Americans to take advantage of negotiations that do not reflect their own circumstances or choices about healthcare provision and prevention.

The post Executive action may actually drive up medicines prices appeared first on Medika Life.

It’s frustrating, but setbacks often come with silver linings. There’s always next season, another chance to try the restaurant, or new prospects waiting on the horizon.

But what happens when the stakes are higher? When the failure to achieve a critical goal means more than a personal letdown — it threatens the very foundation of your work?

Imagine your technology fails to get the certification needed to hit the market, putting your startup’s survival in jeopardy. Or the policy you’d counted on to support your market entry doesn’t pass, leaving you to face an uphill battle.

Or, how about the world’s biggest economy pulling back from collective climate action?

Facing a New Reality

For innovators around the globe, the shifting priorities of the US Federal government vis-à-vis climate action struck a blow. Policies like withdrawing from the Paris Agreement (again), reducing investments in clean energy infrastructure, and pivoting back to fossil fuels have left many in the climate sector on edge.

But these challenges are a call for resilience and persistence. For the climate tech sector, this isn’t just about political setbacks — it’s about reimagining its role in a world where change is constant, risks are high, and opportunities are emerging in unexpected places.

The question isn’t whether climate action will continue; it’s about who will lead it and where innovation can make the greatest impact.

We are entering a new reality. Whether that reality is good or bad is a matter or perspective and priorities — completely subjective.

What is clear is that the world is facing new challenges related to climate –more destructive and unpredictable wildfires, increased desertification, more plastic littering the environment and entering our food systems and our bodies, and biodiversity at risk from all manner of pollution. Our natural ecosystems are out of balance and we see the impact — wildfires, floods and excessive heat.

To put it differently, we are faced with a serious set of unmet needs. And when there are unmet needs, there is an opportunity for innovation. And very few do innovation better than Israel — a testing ground for climate innovations for decades.

Global Climate Action Will Continue to Set the Course

Even as the US Federal government reconsiders its role in global climate action, the momentum hasn’t stopped. Instead, leadership has diversified. States, nations, corporations and individuals are stepping up, creating a dynamic environment where businesses must adapt and pivot to new opportunities.

For instance, The United States Climate Alliance — a group of 24 bi-partisan governors representing 60% of the US economy, have made clear that climate action will continue in the United States, albeit, state-led. Former mayor of New York City, and billionaire philanthropist Michael Bloomberg, has committed, together with other US climate donors, to help cover the United States’ financial commitments to the United Nations Framework Convention on Climate Change.

The US Isn’t the Only Player in the Game

The European Union continues to exhibit strong leadership in transitioning its economy. Policies including the Carbon Border Adjustment Mechanism (CBAM) and the EU’s Green Deal will put Europe on track to be the first climate-neutral continent by 2050.

China has become a world leader in solar energy, and a leading producer of wind turbines and electric vehicles, driving the global shift to clean energy. The country is investing in its green infrastructure, aiming to reach carbon neutrality by 2060.

For climate innovators in general, and Israeli entrepreneurs specifically, understanding how to do business in these markets will be essential in the coming years. Climatetech companies should dedicate some resources to understanding these markets of opportunity.

The Resilience of Climate Investors: US, EU and Israel

Despite some big players pulling back, and investment in climate tech trending down, many investors see the sector as a critical component of a diverse portfolio, not just because it’s good for the planet, but because it makes business sense.

The overall climate investment ecosystem is strong. Breakthrough Energy Venture, founded by Bill Gates, has not slowed on its commitment to reach Net Zero by 2050, raising an $839M fund in August 2024. AllianzGI and the European Investment Bank just raised €450M for climate action in emerging markets. A slew of early-stage VCs are ready to invest in the next climate dream.

Israeli investors, too, have shown confidence in the climatetech sector, backing technologies that promise to reshape the future of climate action. Firms like Ibex Investors, E44 Ventures, Jibe Ventures, and iKare Innovation continue to invest in new climatetech solutions in clean energy, sustainable farming, carbon capture and water conservation, from early-stage through scale-up and beyond, demonstrating a commitment to both financial returns and global environmental impact.

These Israeli investors are helping bridge the gap between innovation and global markets, positioning Israel as a leader in climatetech solutions, even as some US-based companies face increasing political and regulatory uncertainty.

Why We Need to Double Down on ClimateTech Investment

No matter who is in power, people still need access to clean water, healthy and sustainable food sources, clean air, and safely manufactured products. It’s not only the health of the planet that is at stake but human health as well.

Moreover, unlike solutions of the clean tech past that carried too high a “green premium,” today’s climatetech players understand that to make it, they must have a bullet proof business case. They have to be competitive with the conventional, overwhelmingly fit with existing infrastructures, and as much as possible, not ask people to change their behavior too much, at least in the short term.

The Role of Communications in Navigating Today’s Market

Amid the maelstrom of shifting political, economic, and regulatory conditions, resilience isn’t just about innovation — it’s about effective storytelling. Climatetech companies must do more than develop cutting-edge solutions; they must connect these innovations to the world’s most pressing challenges in a way that inspires action and outline societal and economic value.

Communication is the bridge that connects innovators with investors, policymakers, and communities. It’s what transforms a technology into a must-have solution and builds the trust needed to secure partnerships, investments, and market adoption.

The narrative must be bold, credible, and universal — showing how technology addresses unmet needs, meets the moment of climate urgency, and drives systemic change. By crafting and sharing compelling stories, climatetech leaders can position themselves not just as participants in the climate movement but as indispensable drivers of its success.

The post When Plans Shift: The High Stakes of Climate Innovation appeared first on Medika Life.

This isn’t just about politics; it’s about public health, our ability to foresee and tackle future crises, and the integrity of scientific progress. When information disappears, the imagination about future possibilities disappears, and trust eventually disappears. And when trust erodes, so does our clear path to innovate, treat, and prevent the conditions that threaten human lives.

The Hidden Costs of Scientific Censorship

Censorship in science, medicine, and psychology doesn’t just suppress facts; it stifles breakthroughs. Scientific dissent is often the birthplace of innovation. Imagine if Ignaz Semmelweis had been silenced when he proposed handwashing to prevent infections or if HIV research had been blocked because it challenged biased narratives.

Silencing scientists today means fewer opportunities for tomorrow’s cures. Consider:

• Medical Research and Public Health — Data on Alzheimer’s, STD treatments, and overdose prevention trends guide policies and innovation. If public health agencies quietly remove or limit access to this knowledge, how will researchers or in-the-trenches public health professionals develop new treatments or preventive strategies?
• Environmental and Health Links — Climate change affects respiratory diseases, heat-related illnesses, and infectious disease spread. If we erase data on these connections, we blind policymakers and health providers to the realities they must address.
• Mental Health and Social Science — From trauma to the role of social determinants in disease, psychological research informs how we treat and support people’s wellness and well-being. When access to that knowledge is restricted, so are our tools to address crises like teen suicide and PTSD.

Government Justification — and the Risks of Overreach

While concerns over misinformation and national security are often cited as reasons for limiting public access to specific data, history warns us of the dangers of excessive control. Governments may argue that restricting specific information helps prevent panic, misinformation, or harmful misinterpretations (or, even worse, disinformation). However, when public agencies remove health and science data without transparent discussion, they risk undermining trust and accountability.

The balance between information security and the right to knowledge must be carefully maintained because progress suffers once suppression becomes the norm.

Censorship Kills Creativity — and Delays Life-Saving Discoveries

Discarding certain points of view does more damage than suppressing voice — it suffocates creativity. Science, like art, thrives on curiosity, challenge, and critique. Often, significant breakthroughs in medicine and psychology were once outlier ideas met with skepticism or resistance.

• The Germ Theory of Disease was ridiculed before it revolutionized infection control.
• Helicobacter pylori’s role in ulcers was dismissed — until its discoverers won a Nobel Prize.
• The link between social determinants and mental health was ignored for decades, delaying holistic approaches to care and addressing the needs of populations most at risk for illness.

When institutions decide which ideas deserve visibility, they don’t just silence voices but extinguish innovation sparks. Fear of professional or political backlash discourages scientists from pursuing unconventional theories, slowing progress at a time when the urgency of medical advancements has never been greater. Fear of losing access to grants places outside-the-box thinkers into a smaller world where wondering why and questioning the status quo of disease becomes too risky to contemplate.

The False Promise of ‘Controlling the Narrative’

Some argue that removing certain information prevents misinformation. But proper scientific progress comes from debate, peer review, and constant re-evaluation — not from a government deciding which truths deserve visibility. Mistakes and failures are stepping stones to better approaches and are not institutionalized as “forever approaches” to people’s care.

We live in an era when AI can generate misinformation faster than fact-checkers can catch it. But the solution isn’t erasure; it’s education. Censorship doesn’t correct falsehoods; it breeds skepticism and fuels conspiracy theories. Timely transparency, however, builds credibility, trust, and working communities around solutions.

When institutions decide which ideas deserve visibility, they don’t just silence voices; they extinguish sparks of innovation. Fear of professional or political backlash discourages scientists from pursuing unconventional theories, slowing progress at a time when the urgency of medical advancements has never been greater. Remember McCarthyism in US history — the Great Red Scare? How did that play out in Hollywood and politics? Not well.

What’s at Stake? Our Future

If researchers cannot access past data, how can they track disease patterns or health trends? How can medical professionals provide the best care if they lose access to evolving best practices? If scientists fear retribution for discussing controversial topics, how will we ever challenge flawed assumptions and advance knowledge?

Censorship is the enemy of innovation. It does not protect people; it weakens them. Progress depends on an open marketplace of ideas, where competing viewpoints sharpen theories, refine treatments, and spark breakthroughs. If we allow the erasure of uncomfortable or politically inconvenient knowledge, we risk living in a world where the next significant medical advance never sees the light of day.

Knowledge is not a partisan issue. It is the foundation for human progress. If we start treating scientific inquiry and imagination as something that can be controlled or curated, we lose history and the future.

The post The Silent Threat: How Censorship in Medicine, Science, and Psychology Endangers Innovation and Public Health appeared first on Medika Life.

A Changing Landscape: Opportunities in U.S.-India Health Ties

India’s rapidly evolving health sector and the U.S.’s unparalleled expertise in innovation and investment create a powerful synergy. India, already a global leader in pharmaceuticals, supplies 40% of generics to the U.S. and has emerged as a hub for cutting-edge manufacturing and research. Meanwhile, U.S. companies view India as a gateway to growth, with its burgeoning middle class, aging population of over 100 million, and a health market projected to reach $638 billion by 2025, growing at a 22% compound annual growth rate. The results of U.S. elections will directly influence health policies, including tariffs, trade agreements, and investment incentives, shaping the pace of collaboration between the two nations. Multinationals must navigate these shifts carefully, balancing policy changes with market potential.

Emerging Trends in the US-India Health Partnership

Reshaping the Pharmaceutical Supply Chain: With the U.S. increasing tariffs on Chinese imports and emphasizing domestic resilience, India has an unprecedented opportunity to fill the gap. Proposed legislation like the U.S. BIOSECURE Act positions India as a vital partner in contract manufacturing and research, doubling opportunities for Indian CDMOs and CROs. 

Incentivizing Innovation and Local Production: India’s Production Linked Incentive (PLI) and Make in India initiatives are revolutionizing domestic manufacturing. These schemes offer MNCs financial incentives to produce locally, reducing costs and enhancing access. U.S. companies like Pfizer and GSK have already capitalized on India’s pro-business policies, paving the way for others to follow.

Digital Health Revolution: India’s National Digital Health Mission and growing investments in telemedicine present lucrative opportunities for U.S. firms. Collaborating with India’s thriving tech ecosystem could help MNCs expand their digital health solutions, from AI-driven diagnostics to telehealth platforms, addressing unmet needs in rural and underserved markets.

Medical Devices as the Next Frontier: India’s recent ₹500 crore initiative to strengthen its medical devices sector aligns with U.S. expertise in advanced technologies. Partnerships in this space could make India a global exporter of high-quality medical devices, with MNCs playing a pivotal role in innovation and scale.

Why India is Unmissable for Multinationals

India’s health sector is undergoing a profound transformation, bolstered by government-led reforms and a favorable FDI regime. The allowance of 100% foreign direct investment through automatic routes in health and related sectors has already attracted global giants. Regulatory relaxations, such as waiving clinical trial requirements for drugs approved in select countries, make India an even more attractive destination for innovation. Additionally, India’s ambitious BIO-Ride Scheme aims to bridge the gap between research and commercialization, enhancing the country’s reputation as a biomanufacturing powerhouse. These developments, coupled with the expanding talent pool, provide multinationals with access to skilled professionals and cutting-edge research.

While the U.S.-India health partnership offers immense promise, challenges such as regulatory hurdles, intellectual property concerns, and geopolitical shifts must be addressed. Multinationals must adopt a strategic approach to align their goals with India’s priorities, from affordability to local capacity building. The future of health lies in the strength of the U.S.-India relationship. Together, the two nations can drive transformative change, addressing global health challenges through innovation, policy alignment, and mutual investment. Multinationals that recognize and act on this potential will not only unlock significant growth but also play a defining role in shaping the health landscape for generations.

As the post-election dust settles, one thing is clear: the U.S.-India health partnership is not just a bilateral opportunity—it’s a global imperative.

The post US -India Health Partnerships: A Blueprint for Global Health Innovation appeared first on Medika Life.

Additionally, in a recent AT&T survey, business leaders in healthcare reached a similar conclusion. The survey found that the lack of a unified strategy was the dominant challenge in digital transformation. This strategic obstacle was five times greater than commonly cited examples, such as “required expertise,” and about 10 times greater than an “ROI justification” for the expense. In other words, organizations may have the resources to drive change, but fail to have a coherent strategy to implement digital transformation.

Even when organizations can overcome these hurdles, one major challenge remains: focus and prioritization. In many boardrooms, executives are debating overwhelming lists of potential generative AI investments, only to deem them incomplete or outdated given the dizzying pace of innovation. These protracted debates are a waste of precious organizational energy—and time.

The Rudderless Ship: A Metaphor for Healthcare’s Digital Journey

The complexity and lack of strategic coherence in healthcare’s digital transformation can be likened to a ship without a rudder. It may be powered by the finest engines and loaded with the most sophisticated technology, but without a rudder to steer, the vessel is aimless, unable to reach its desired destination. The healthcare industry is a vessel brimming with technological promise but adrift in a sea of strategic ambiguity.  And this path is complicated by the turbulent currents of cost, reimbursement, adoption and clinical validation.

The Philosophical Imperative of Innovation

The path forward is critical, but innovation is the fruit of strategic thinking, and this critical process and path can be a significant obstacle in driving critical improvements to our healthcare systems. It’s not merely a matter of technology or investment; it’s a profound philosophical challenge that requires an integration of ethics, creativity, and humanistic understanding.

In the world of healthcare, where lives are at stake, the diffusion of innovation into complex systems is more than a commercial or technological endeavor—it’s a moral and societal one. An approach that intertwines technology, AI, and human empathy is essential for aligning the path of innovation with the needs of patients and the healthcare community.

Navigating the Sea of Change

Navigating the intricate waters of healthcare digital adoption requires more than cutting-edge technology. It requires a compass of strategic wisdom, a rudder of cohesive planning, and the winds of philosophical insight to guide the way.

As the rate of technological change accelerates, a well-defined, unified strategy for digital transformation is not merely a wise business decision; it is an imperative for healthcare’s future. Innovation is not just the tool but the very art of reimagining what healthcare can be. This is the odyssey we must embark upon—an imperative that transcends technology to explore the profound interconnections between the human spirit, the art of healing, and the science of the future.

By seizing the helm and steering with intention and insight, healthcare can find its way. The question that looms is not only if we have the technological capability but whether we have the philosophical depth and the human wisdom to chart the course. Only then can we truly transform healthcare and reach the shores of a new era.

The post Is Healthcare Digital Innovation Adrift Without a Rudder? appeared first on Medika Life.

When it comes to digital health, I see two critical realities.  The first is around the amazing opportunities in technology and health that will change the face of medicine.  The second is the marketing opportunity—no, marketing imperative to empower innovation with communication.  Yet my concern is that many innovators rely on the “power of the device” to drive adoption.  The strategy is simple—build it and they will come.  The problem starts with “it”.  Defining a digital health device beyond a sensor requires a solid understanding of the market.  And translating a core feature to a higher order benefit and/or value can be tricky. And this becomes even more complicated when parity devices fight for market share on based less on technology and more on brand position and personality. 

“A great product without great marketing is like winking at someone in the dark.  You known what you’re doing it, but no one else does!”

The other part of this simple statement is the “they”.  After you build it, just who is “they”?  The simple answer in digital health is often the patient—or consumer.  After all, it’s the era of patient empowerment where the individual stands up for their health and takes control.  Right?  Nope.  Many devices and newborn brands rely on this assumption and move to market with a single-minded strategy that doesn’t take into consideration the complicated buying process that engages both the rational and emotional decision-makers.  Simply put, the audience for digital health is a complex array of stakeholders—from the patient and caregiver to the physician and payor.  And one of the biggest challenges can be audience stratification and resource allocation. 

“To simple avoid the health care provider and expect the patient to drive adoption is risky.”

One thing is for sure.  Like a device itself, one size doesn’t fit all.  The role of the healthcare provider can be a critical path to driving adoption and long-term use.  Yet, in other instances, the validation by parents can be equally as powerful. The key is to leverage key influencers in a meaningful way.

“Products live on shelves and brands live in our minds–mindshare always precedes market share.”

The power of innovation, medicine and the entire digital health movement is a function of the story we all craft. And that story can be as simple or complex as we want.  Certainly, the technology exists to manufacture many interesting and important devices. But these devices will always live on a shelf.  It’s the brands that will live in the minds of our customers.  Let’s make sure that we empower digital health with the resonant communication it deserves.

The post The Dangerous Myth of Digital Health Innovation: Build It And They Will Come appeared first on Medika Life.

Digital Health Interviews: Levi Shapiro and Ellie Hanson on Digital Health in Israel

This new episode of Digital Health, hosted by Ukrainian health innovation leader Alex Koshykov, focuses on the topic of digital health in Israel. Guests are mHealth Israel Founder Levi Shapiro and FINN Partners Partner Ellie Hanson. Together, they discuss the current situation in the digital health market in Israel, how government helps startups in their early stages, and what are the main differences between American and Israeli health systems.

Ellie provides a short intro to a marketing strategy for digital health startups while Levi gave lots of useful tips for startup founders.

The post Digital Health Interviews: Levi Shapiro & Ellie Hanson – Digital Health in Israel appeared first on Medika Life.

NEW YORK, Jan. 11, 2022 /PRNewswire/ — — The Galien Foundation, the premier global institution dedicated to honor innovators in life sciences, today announced a new Prix Galien Award category dedicated to “Incubators, Accelerators and Equity.”  This newest honor acknowledges the role played by these institutions in guiding the next wave of innovators by offering a range of mentoring skills including clinical trial design expertise, legal counsel, lab space, professional development, peer-to-peer support, free access to leading advisors and economic support to advance life science innovation.

Globally, incubators and accelerators have stepped in to play a pivotal role in the development of innovative solutions to the healthcare sector challenges of the 21st century. There are more than 4,000 incubators and accelerators worldwide, and some 1,800 in the United States alone. Academic institutions, major medical centers, large life science companies have launched incubators and accelerators to offer a guiding hand in the future of innovation – supporting biotech, digital health, health information and medical device start-ups – to have a stronger influence on the future of ideas that can improve human health.

“The addition of this new Prix Galien category reinforces the critical importance of academia and industry insight and experience to support the future and adaptation of bold, life-changing ideas that can improve humans’ wellness and health,” said Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth, Chairman of the Prix Galien, who leads the Prix Galien Start-Up & Digital Awards Category. “Galien is at the forefront of measuring the power of ideas and innovation to impact human life.  Many of the world’s life-changing ideas accelerate from drawing board to major companies’ board rooms thanks to support from academia, industry mentors and private equity business guidance.”

“The Galien Foundation curates the best jurors, with decades of proven experience in the industry categories that we recognize for outstanding achievement. The Foundation creates an environment that nurtures and honors institutions for championing biomedical, digital health, and medical device excellence,” said Bruno Cohen, Chairman of The Galien Foundation.  “Science and innovation are fragile states that require support at different levels to press forward and succeed.  This new category is an essential part of the life-giving and sustaining innovation environment.”

“Today, an innovator’s connection to an accelerator, incubator or equity organization is a strong indicator for success,” said Gil Bashe, Chair Global Health, FINN Partners, and Prix Galien Incubators, Accelerators and Equity Committee Sub-Committee Chair. “Money itself is not sufficient to understand how to design the right clinical trials for regulatory approval, navigate the complexities of the payer system or build a marketing plan. The wisdom and experience offered by incubators, accelerators and hands-on equity groups is the game-changer to address unmet patient needs.”

Judges will evaluate submissions using these seven criteria alongside a candidate’s 800-word entry together with supporting documents: 

1. Information about the program/fund, its origins, philosophy, clinical or sector focus (e.g., biotechnology, digital health, medical device) and length of support
2. Background on how you accept, support and address the needs of candidates or portfolio companies accepted
3. Explain how you benchmark success during the incubation or acceleration or funding period
4. Note resources provided to companies in the program – e.g., financial, housing, clinical, legal and communications
5. Outline financial structure with entrepreneurs into the future – equity or royalties
6. If applicable, offer information on the number of funds raised for your cohort of portfolio businesses – Series A or B and other funding rounds
7. Examples of businesses that have “graduated” or “exited” from the incubator and/or accelerator

To learn more about the new award category and nominate an outstanding Accelerator, Incubator and Venture Fund demonstrating an ability to advance health innovation, please visit http://candidates.prix-galien-usa.com/

Prix Galien Start-Up Digital Health Category
Bernard Poussot – Start-Up & Digital Awards Jury Chair
Director, Roche Holding, Former Chairman & CEO, Wyeth
Chairman

Prix Galien Incubators, Accelerators and Equity Category Sub Committee

Gil Bashe
Managing Partner, Chair Global Health, Finn Partners
Sub-Committee Jury Chair

Ron Cohen, M.D.
Founder, President & CEO, Acordia Therapeutics

Jamey Edwards
Former CEO, Emergent Medical Associates

Amir Kalali, M.D.
Chairman & Chief Curator, CNS Summit/Co-Chair, Decentralized Trial Research Alliance

Michelle Longmire, M.D.
Co-Founder & CEO, Medable Inc.

Cheryl Pegus, M.D.
Executive Vice President of Health & Wellness, Walmart

James Prutow, J.D., MBA
Advisory Partner – Life Sciences, Molecular Diagnostics, Global Healthcare, PwC Consulting

About The Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.

The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media: https://www.facebook.com/GalienFoundation/ 
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/

SOURCE The Galien Foundation

The post Galien Foundation Announces New Prix Galien Award Category, “Incubators, Accelerators and Equity – Foundational Support for Health Innovation” appeared first on Medika Life.